Research Output Journal of Biological and Applied Science 4(1):27-32, 2024

ROJBAS Publications ONLINE ISSN: 1115-9200

https://rojournals.org/roj-biological-and-applied-science/ PRINT ISSN: 1115-6120

An Overview of Diabetes Types, Management of Type 1 Diabetes, and its Impact

Irakoze Mukamana S.

School of Applied Health Sciences Kampala International University Uganda

ABSTRACT

Diabetes mellitus, a complex, and growing global health challenge, manifests in various forms, each with distinct causes, progression, and management strategies. This review provides a comprehensive overview of diabetes types, with a particular focus on the management of Type 1 Diabetes (T1D) and its profound impact on individuals' lives. T1D, an autoimmune disorder that typically arises in childhood or adolescence, necessitates lifelong insulin therapy due to the destruction of insulin-producing beta cells in the pancreas. The review explores the classification of diabetes, highlighting the differences in etiology, pathophysiology, and management across the major types: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes Mellitus, and other specific forms of diabetes. The management of T1D involves a multifaceted approach, including advanced insulin delivery systems, continuous glucose monitoring technologies, and lifestyle modifications. Despite advancements in diabetes care, T1D significantly impacts individuals' physical health, psychological well-being, and social life. The relentless demands of managing T1D, coupled with the risk of acute complications such as hypoglycemia and diabetic ketoacidosis, contribute to physical and emotional strain. Additionally, the disease's social and lifestyle implications, including the stigma associated with chronic illness, further complicate the lived experience of those with T1D. This review underscores the importance of integrated care approaches that address both the physical and psychological aspects of T1D, aiming to enhance the quality of life for affected individuals.

Keywords: Diabetes, Type 1 Diabetes, Impact, Individuals' Lives

INTRODUCTION

Diabetes mellitus stands as one of the most pressing global health challenges, with its prevalence and incidence rising at an alarming rate. This chronic condition, characterized by high blood glucose levels, manifests in various forms, each with distinct causes, progression, and management strategies [1] [2]. Among these, Type 1 Diabetes (T1D) holds a unique position due to its autoimmune nature, typically onset during childhood or adolescence, and the lifelong dependence on insulin therapy it necessitates [3]. This review seeks to provide a detailed overview of the different types of diabetes, with a particular focus on the management of Type 1 Diabetes and its profound impact on individuals' lives.

CLASSIFICATION OF DIABETES MELLITUS

Diabetes mellitus is classified into four main types, each with distinct causes, pathophysiologies, and management strategies [4]. Understanding the differences among these types is critical for appropriate diagnosis, treatment, and long-term management.

Type 1 Diabetes (T1D)

Type 1 Diabetes (T1D), also known as insulin-dependent diabetes or juvenile-onset diabetes, is an autoimmune disease. In this condition, the immune system erroneously targets and destroys the insulin-producing beta cells in the pancreas [4]. Insulin is a crucial hormone that regulates blood sugar by facilitating the uptake of glucose into cells for energy. In the absence of insulin, glucose builds up in the bloodstream, leading to hyperglycemia.

Etiology: The precise cause of T1D remains unclear, but it involves a combination of genetic susceptibility and environmental factors such as viral infections [5]. Certain genes, particularly those related to the human leukocyte antigen (HLA) system, are strongly associated with the risk of developing T1D.

Pathophysiology: T1D is characterized by the autoimmune destruction of beta cells, leading to an absolute insulin deficiency [6]. As the body's capacity to produce insulin declines, blood sugar levels rise, resulting in hyperglycemia. Without intervention, T1D can lead to life-threatening conditions like diabetic ketoacidosis (DKA).

Management: Individuals with T1D require lifelong insulin therapy, administered through injections or an insulin pump. Regular blood sugar monitoring and lifestyle management, including diet and exercise, are essential [7]. Emerging technologies, such as continuous glucose monitors (CGMs) and closed-loop systems (artificial pancreas), are transforming diabetes care by allowing real-time glucose monitoring and automated insulin delivery.

Onset and Prevalence: T1D commonly appears in childhood or adolescence, although it can develop at any age. It accounts for approximately 5-10% of all diabetes cases globally.

Type 2 Diabetes (T2D)

Type 2 Diabetes (T2D) is the most prevalent form of diabetes, affecting 90-95% of individuals with the condition. Unlike T1D, T2D is primarily characterized by insulin resistance, where the body's cells do not respond effectively to insulin [8]. Over time, the pancreas may also produce insufficient insulin to maintain normal glucose levels.

Etiology: T2D is strongly associated with modifiable lifestyle factors such as obesity, physical inactivity, and poor diet. Genetics also play a significant role, as a family history of diabetes increases the risk [9]. Other contributing factors include age, ethnicity, and metabolic conditions like hypertension and dyslipidemia.

Pathophysiology: Insulin resistance in T2D leads to elevated blood glucose levels, as the body's cells fail to use insulin efficiently. Over time, beta cells in the pancreas become overworked, resulting in a relative insulin deficiency [10]. The progressive nature of T2D can eventually lead to both insulin resistance and impaired insulin production, further exacerbating hyperglycemia.

Management: Treatment for T2D begins with lifestyle modifications, including diet and exercise, aimed at improving insulin sensitivity. Oral medications such as metformin, sulfonylureas, and newer agents like GLP-1 receptor agonists are commonly used to lower blood glucose levels [11]. Insulin therapy may become necessary as the disease progresses. Weight management and physical activity are crucial for mitigating insulin resistance.

Prevalence and Trends: T2D primarily affects adults, but its incidence in children and adolescents has risen sharply due to the global obesity epidemic. Urbanization and sedentary lifestyles have contributed to its widespread prevalence, particularly in low- and middle-income countries [12].

Gestational Diabetes Mellitus (GDM)

Gestational Diabetes Mellitus (GDM) is a temporary form of diabetes that occurs during pregnancy. GDM typically arises in the second or third trimester when pregnancy-related hormonal changes lead to insulin resistance.

Etiology: During pregnancy, placental hormones can interfere with insulin's effectiveness, leading to hyperglycemia [13]. Women with risk factors such as obesity, advanced maternal age, and a family history of diabetes are more likely to develop GDM.

Pathophysiology: The hormonal changes associated with pregnancy increase insulin resistance, and in some women, the pancreas cannot produce enough insulin to overcome this resistance [14]. This results in elevated blood sugar levels, which can pose risks to both the mother and the fetus, including macrosomia (large baby), premature birth, and complications during delivery.

Management: GDM is typically managed through diet and exercise, although insulin or oral hypoglycemic agents may be required if blood sugar levels cannot be controlled through lifestyle modifications alone [15]. Monitoring blood glucose levels is essential to ensure that both mother and baby remain healthy throughout the pregnancy.

Impact on Long-Term Health: Although GDM usually resolves after childbirth, women who experience it have a higher risk of developing T2D later in life. Additionally, children born to mothers with GDM are at increased risk of obesity and developing T2D in the future [16].

OTHER SPECIFIC TYPES OF DIABETES

This category encompasses rare forms of diabetes with distinct causes. These conditions may involve genetic mutations, diseases of the pancreas, or external factors like medications.

Monogenic Diabetes Syndromes: These are caused by mutations in a single gene and include conditions like Maturity-Onset Diabetes of the Young (MODY). Unlike T1D or T2D, these forms of diabetes often develop at a younger age but have a more predictable course and can sometimes be managed with oral medications rather than insulin [17].

Diseases of the Exocrine Pancreas: Conditions such as pancreatitis, cystic fibrosis, or pancreatic cancer can damage the insulin-producing cells of the pancreas, leading to diabetes.
Drug- or Chemical-Induced Diabetes: Certain medications, such as corticosteroids or antipsychotic drugs, can induce hyperglycemia and, over time, lead to diabetes.
Management and Diagnosis: These specific types of diabetes require targeted diagnostic tools, including genetic testing, and may demand specialized treatments based on the underlying cause [18]. Understanding the root of these forms is crucial for effective treatment and prevention of complications.

MANAGEMENT OF TYPE 1 DIABETES

Type 1 Diabetes (T1D) management involves a comprehensive approach that includes insulin therapy, advanced monitoring technologies, lifestyle adjustments, and adjunctive therapies. The primary goals are to maintain blood glucose levels within a target range, minimize the risk of complications, and enhance the quality of life for individuals with T1D. Insulin therapy is the cornerstone of T1D management, as individuals cannot produce their own insulin due to the autoimmune destruction of pancreatic beta cells [19]. There are various types of insulin, including rapid-acting, short-acting, intermediate-acting, long-acting, basal-bolus, and premixed insulins. Continuous Glucose Monitoring (CGM) systems and insulin pumps have significantly improved outcomes and quality of life for individuals with T1D. CGM devices continuously monitor blood glucose levels, providing real-time data, which enables more precise insulin dosing and helps individuals make informed decisions about their insulin therapy, diet, and activity levels. Insulin pumps offer greater flexibility in managing blood glucose levels compared to multiple daily injections (MDI). However, they require ongoing management and maintenance, including regular site changes and monitoring for device malfunctions [20]. Adjunctive therapies are being explored to enhance glucose control and reduce the burden of disease. Immunomodulatory therapies aim to preserve residual beta-cell function and slow the progression of T1D by modulating the immune response. Incretin-based therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, have shown potential benefits in T1D by enhancing insulin secretion, reducing glucagon levels, and promoting weight loss. However, these therapies carry a risk of diabetic ketoacidosis (DKA) in individuals with T1D, requiring careful patient selection and monitoring.

EFFECTS OF TYPE 1 DIABETES ON INDIVIDUALS' LIVES

Physical Impact

Type 1 Diabetes (T1D) has a significant physical impact, requiring ongoing management and vigilance to prevent short-term and long-term complications. The daily routine for individuals with T1D includes frequent blood glucose monitoring, insulin administration, and managing dietary intake and physical activity [21]. This constant need for attention can be exhausting, as fluctuations in glucose levels can lead to acute complications such as hypoglycemia and diabetic ketoacidosis (DKA). Hypoglycemia occurs when blood glucose levels drop too low, causing symptoms such as shakiness, sweating, confusion, and loss of consciousness. DKA, a potentially life-threatening complication, occurs when the body produces high levels of ketones due to a lack of insulin, leading to the breakdown of fat as an alternative energy source. DKA requires urgent medical attention and is a major cause of hospitalizations among T1D patients [22]. Long-term complications include cardiovascular disease (CVD), diabetic nephropathy, diabetic neuropathy, and diabetic retinopathy. The physical toll of T1D is not limited to the complications themselves but also includes the burden of preventing these complications through stringent self-management practices. The constant need for vigilance can lead to physical fatigue and contribute to the overall burden of the disease [23].

Psychological and Emotional Impact

Diabetes mellitus (T1D) has a profound psychological and emotional impact, often underestimated. The relentless demands of managing T1D can lead to significant mental health challenges, including stress, anxiety, depression, and burnout. Chronic stress and anxiety stem from the need for continuous monitoring of blood glucose levels, fear of hypoglycemia, and the responsibility of managing insulin therapy [24]. Diabetes distress, a term used to describe the emotional burden of living with a chronic illness, can manifest as feelings of being overwhelmed by daily tasks and concern about long-term complications. Diabetes burnout is a state of physical and emotional exhaustion caused by the demands of diabetes management. Individuals with T1D are at a higher risk of developing depression, which can complicate diabetes management by reducing motivation to adhere to treatment regimens and exacerbating feelings of hopelessness and frustration [25, 26, 27, 28]. The bidirectional relationship between depression and T1D can create a vicious cycle, where poor diabetes management leads to worsening mental health and vice versa. The psychological burden of T1D significantly impacts the quality of life, as the constant need for self-management and fear of complications can lead to a diminished sense of well-being. Integrated care that addresses both physical and psychological aspects of the disease is essential.

Social and Lifestyle Impact

Type 1 Diabetes (T1D) has a significant social and lifestyle impact, affecting daily life, work, and personal relationships. Managing T1D in social settings can be challenging due to the need to monitor blood glucose levels, administer insulin, and make dietary choices that may differ from others [29, 30]. This can lead to feelings of self-consciousness or embarrassment, especially in public or unfamiliar settings. Stigma and discrimination can also arise due to chronic illness, which can manifest as discrimination in the workplace, educational settings, or social interactions. Misconceptions about diabetes, such as the belief that it is solely caused by poor lifestyle choices, can contribute to this stigma, affecting self-esteem and social relationships [31, 32]. T1D can affect personal relationships, including those with family members, friends, and romantic partners. Supportive relationships are crucial for effective diabetes management and can improve outcomes and quality of life. Lifestyle adjustments, such as dietary modifications and regular physical activity, can be socially isolating if they limit participation in activities others enjoy. T1D can also impact employment opportunities and workplace dynamics [33]. The need for regular breaks to monitor blood glucose levels or administer insulin, the potential for hypoglycemic episodes, and the time required for medical appointments can impact job performance and satisfaction. In some cases, individuals may face discrimination or challenges in securing employment due to their condition [30, 31, 32, 33].

CONCLUSION

Diabetes mellitus is a multifaceted disease with significant variations in etiology, pathophysiology, and management across its different types. Type 1 Diabetes (T1D), characterized by an autoimmune destruction of pancreatic beta cells, presents unique challenges that require lifelong insulin therapy and diligent self-management. Advances in technology, such as continuous glucose monitors and insulin pumps, have improved the quality of life for individuals with T1D, yet the physical, psychological, and social impacts of the disease remain profound. The physical demands of constant blood glucose monitoring, the risk of acute and chronic complications, and the psychological burden of managing a chronic illness contribute to a complex and often overwhelming experience for those affected. Furthermore, the social and lifestyle implications of T1D, including stigma, discrimination, and the challenges of maintaining personal and professional relationships, underscore the need for comprehensive care that addresses not only the medical but also the emotional and social needs of individuals with diabetes. Future advancements in T1D management, particularly in immunomodulatory therapies and artificial pancreas systems, hold promise for reducing the burden of this condition. However, continued efforts are needed to support individuals with T1D through integrated care approaches that encompass physical health, mental well-being, and social support. By fostering a more holistic understanding and management of T1D, we can enhance the quality of life for those living with this challenging condition and reduce its impact on individuals' lives.

REFERENCES

1. Aja, P. M., Ani, O. G., Offor, C. E., Orji, U. O., Alum, E. U. Evaluation of Anti-Diabetic Effect and Liver Enzymes Activity of Ethanol Extract of Pterocarpussantalinoides in Alloxan Induced Diabetic Albino Rats. Global Journal of Biotechnology & Biochemistry. 2015;10 (2): 77-83. DOI: 10.5829/idosi.gjbb.2015.10.02.93128.
2. Atkinson, M. A., Eisenbarth, G. S., & Michels, A. W. (2023). Type 1 diabetes. The Lancet, 391(10138), 2449-2462. doi:10.1016/S0140-6736(18)31320-5.
3. Uti, D. E., Igile, G. O., Omang, W. A., Umoru, G. U., Udeozor, P. A., Obeten, U. N., Ogbonna, O. N., Ibiam U. A., Alum, E. U.,Ohunene, O. R., Chukwufumnanya, M. J., Oplekwu, R. I. and Obio, W. A.Anti-Diabetic Potentials of Vernonioside E Saponin; A Biochemical Study. Natural Volatiles and Essential Oils. 2021; 8(4): 14234-14254.
4. Alum, E. U., Umoru, G. U., Uti, D. E., Aja, P. M., Ugwu, O. P., Orji, O. U., Nwali, B. U., Ezeani, N., Edwin, N., Orinya, F. O.Hepato-protective effect of Ethanol Leaf Extract of Daturastramonium in Alloxan-induced Diabetic Albino Rats. Journal of Chemical Society of Nigeria. 2022; 47 (3): 1165 – 1176. https://doi.org/10.46602/jcsn.v47i5.819.
5. Ugwu, O. P.C., Alum, E. U.,Okon, M. B., Aja, P. M., Obeagu, E. I. and Onyeneke, E. C. Ethanol root extract and fractions of Sphenocentrumjollyanum abrogate hyperglycemia and low body weight in Streptozotocin-induced diabetic Wistar albino Rats, RPS Pharmacy and Pharmacology Reports. 2023; 2,1-6.https://doi.org/10.1093/rpsppr/rqad010.
6. Gregory, J. M., Moore, D. J., Simmons, J. H., & Kovatchev, B. P. (2022). Advances in Type 1 Diabetes Technology: Artificial Pancreas and CGM. Diabetes Technology & Therapeutics, 24(3), 177-186. doi:10.1089/dia.2021.0331.
7. Dabelea, D., Mayer-Davis, E. J., Saydah, S., Imperatore, G., Linder, B., Divers, J., & Hamman, R. F. (2023). Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2017. JAMA, 322(6), 572-582. doi:10.1001/jama.2023.14606.

8. Ezeani, N, N., Alum, E, U., Orji, O, U., Edwin, N. The Effect of Ethanol Leaf Extract of Pterocarpussantalinoids (Ntrukpa) on the Lipid Profile of Alloxan-Induced Diabetic Albino Rats. International Digital Organization for Scientific Research Journal of Scientific Research. 2017; 2 (2): 175-189. www.idosr.org. https://www.idosr.org/wp-content/uploads/2017/07/IDOSR-JSR-22-175-189-2017-EZEANI-updated.pdf
9. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I., Aja, P. M., Ugwu, C. N., Okon, M.B.Nutritional Care in Diabetes Mellitus: A Comprehensive Guide.International Journal of Innovative and Applied Research. 2023; 11(12):16-25.Article DOI: 10.58538/IJIAR/2057 DOI URL: http://dx.doi.org/10.58538/IJIAR/2057.
10. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandiyan, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR Experimental Sciences.2023; 12(2):214-224. https://doi.org/10.59298/INOSRES/2023/2.17.1000.
11. Tauschmann, M., & Hovorka, R. (2023). Continuous glucose monitoring in children and adolescents with Type 1 Diabetes. Diabetes Care, 42(9), 1639-1646. doi:10.2337/dc19-0945.
12. Majidi, S., Ebekozien, O., Clements, M., Klingensmith, G. J., & Alonso, G. T. (2023). Psychological Impacts of Type 1 Diabetes in Adolescents and Emerging Adults. Current Diabetes Reports, 19(6), 15-25. doi:10.1007/s11892-023-01454-3.
13. Agbafor, K. N., Onuoha, S. C., Ominyi, M. C., Orinya, O. F., Ezeani, N. and Alum, E. U.Antidiabetic, Hypolipidemic and Antiathrogenic Properties of Leaf Extracts of Ageratum conyzoides in Streptozotocin-Induced diabetic rats. International Journal of Current Microbiology and Applied Sciences. 2015; 4 (11):816-824. http://www.ijcmas.com. https://www.ijcmas.com/vol-4-11/Agbafor,%20K.%20N,%20et%20al.pdf
14. Offor, C. E., Ugwu, O. P. C., Alum, E. U. The Anti-Diabetic Effect of Ethanol Leaf-Extract of Allium sativum on Albino Rats. International Journal of Pharmacy and Medical Sciences. 2014; 4 (1): 01-03. DOI: 10.5829/idosi.ijpms.2014.4.1.1103.
15. Obeagu, E. I., Scott, G. Y., Amekpor, F., Ugwu, O. P. C., Alum, E. U. COVID-19 infection and Diabetes: A Current Issue. International Journal of Innovative and Applied Research. 2023; 11(01): 25-30. DOI: 10.58538/IJIAR/2007. DOI URL: http://dx.doi.org/10.58538/IJIAR/2007.
16. Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., & Tuomilehto, J. (2023). Type 1 diabetes mellitus. Nature Reviews Disease Primers, 7(1), 1-19. doi:10.1038/s41572-023-00282-2.
17. Lawrence, J. M., Divers, J., Isom, S., Saydah, S. H., Imperatore, G., Pihoker, C., & Dabelea, D. (2022). Trends in Incidence of Type 1 Diabetes Among Non-Hispanic White Youth in the US, 2002-2018. JAMA, 326(8), 729-738. doi:10.1001/jama.2022.11627.
18. Chiang, J. L., Maahs, D. M., Garvey, K. C., Hood, K. K., Laffel, L. M., Weinzimer, S. A., & Schatz, D. A. (2023). Type 1 Diabetes through the Life Span: A Position Statement of the American Diabetes Association. Diabetes Care, 41(9), 2026-2044. doi:10.2337/dci18-0023.
19. Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., & DuBose, S. N. (2022). State of type 1 diabetes management and outcomes from the T1D Exchange in 2021-2022. Diabetes Technology & Therapeutics, 24(3), 120-127. doi:10.1089/dia.2021.0478.
20. Prahalad, P., Tanenbaum, M. L., Hood, K. K., & Maahs, D. M. (2023). Diabetes-related distress in adolescents with Type 1 Diabetes: The role of social support and self-management. Diabetes Research and Clinical Practice, 156, 107822. doi:10.1016/j.diabres.2023.107822.
21. Obeagu, E. I., Ugwu, O. P. C., Alum, E. U. Poor glycaemic control among diabetic patients; A review on associated factors. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023; 3(1):30-33. https://nijournals.org/newport-international-journal-of-research-in-medical-sciences-nijrms-volume-3-issue-1-2023/.
22. Aja, P. M., Igwenyi, I. O., Ugwu, O. P. C., Orji, O. U., Alum, E. U. Evaluation of Anti-diabetic Effect and Liver Function Indices of Ethanol Extracts of Moringaoleifera and Cajanuscajan Leaves in Alloxan Induced Diabetic Albino Rats. Global Veterinaria. 2015;14(3): 439-447. DOI: 10.5829/idosi.gv.2015.14.03.93129.
23. Ugwu, O. P.C., Alum, E. U., Obeagu, E. I, Okon, M. B., Aja, P. M., Samson, A. O., Amusa, M. O. and Adepoju, A. O. Effect of Ethanol Leaf Extract of Chromolaenaodorata on hepatic markers in streptozotocin-induced diabetic wistar albino rats. IAA Journal of Applied Sciences, 2023; 9(1):46-56. https://doi.org/10.5281/zenodo.7811625

24. Egwu, C. O., Offor, C. E. and Alum, E. U. Anti-diabetic effects of Buchholziacoriacea ethanol seed Extract and Vildagliptin on Alloxan-induced diabetic albino Rats. International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS). 2017; 6 (6): 1304-1314. www.ijbpas.com. https://ijbpas.com/pdf/2017/June/1497506120MS%20IJBPAS%202017%204202.pdf
25. Ugwu O, P, C., Alum, E, U., Obeagu, E, I., Okon, M, B., Aja, P, M., Samson, A, O., Amusa, M, O., Adepoju, A, O. Effect of Ethanol leaf extract of Chromolaenaodorata on lipid profile of streptozotocin induced diabetic wistar albino rats.IAA Journal of Biological Sciences. 2023;10(1):109-117. https://www.iaajournals.org/wp-content/uploads/2023/03/IAAJB-101109-117-2023-Effect-of-Ethanol-leaf-extract-of-Chromolaena-odorata-on-lipid-profile-of-streptozotocin-induced-diabetic-wistar-albino-rats..docx.pdf.
26. Ezeani, N, N., Edwin, N., Alum, E, U., Orji, O, U, Ugwu, O, P, C., Effect of Ethanol Leaf Extract of Ocimumgratissmum (Scent Leaf) on Lipid Profile of Alloxan-Induced Diabetic Rats. International Digital Organization for Scientific Research Journal of Experimental Sciences, 2017; 2 (1): 164-179. www.idosr.org. https://www.idosr.org/wp-content/uploads/2017/07/IDOSR-JES-21-164-179-2017.-ezeani-2-updated.pdf
27. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long Term Implications of Gestational Diabetes Mellitus.INOSR Scientific Research. 2024; 11(1):63-71.https://doi.org/10.59298/INOSRSR/2024/1.1.16371
28. Ugwu, O. P. C., Alum, E. U. and Uhama, K. C. (2024). Dual Burden of Diabetes Mellitus and Malaria: Exploring the Role of Phytochemicals and Vitamins in Disease Management. Research Invention Journal of Research in Medical Sciences. 3(2):38-49.
29. Enechi OC, H Ikenna Oluka, PC Okechukwu Ugwu (2014). Acute toxicity, lipid peroxidation and ameliorative properties of Alstonia boonei ethanol leaf extract on the kidney markers of alloxan induced diabetic rats. African journal of biotechnology, 13, 5
30. Adonu CC, OP Ugwu, A Bawa, EC Ossai, AC Nwaka (2013). Intrinsic blood coagulation studies in patients suffering from both diabetes and hypertension. Int Journal of Pharmaceutical Medicine and Bio Science, 2 (2), 36-45
31. Okechukwu Paul-Chima Ugwu, Esther Ugo Alum, Michael Ben Okon, Patrick M Aja, Emmanuel Ifeanyi Obeagu, EC Onyeneke (2023). Ethanol root extract and fractions of Sphenocentrum jollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats Oxford University Press 2(2) 10
32. Ugwu Okechukwu P.C. and Amasiorah V.I. (2020). The effects of the crude ethanol root extract and fractions of Sphenocentrum jollyanum on hematological indices and glycosylated haemoglobin of streptozotocin-induced diabetic. INOSR Scientific Research, 6, (1), 61-74
33. Enechi OC, IH Oluka, OPC Ugwu, YS Omeh (2012). Effect of ethanol leaf extract of Alstonia boonei on the lipid profile of alloxan induced diabetic rats. World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS), 2013, Vol. 2, No. 3, 782-795

CITE AS: Irakoze Mukamana S. (2024). An Overview of Diabetes Types, Management of Type 1 Diabetes, and its Impact. Research Output Journal of Biological and Applied Science 4(1):27-32. https://doi.org/10.59298/ROJBAS/2024/412732